Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Gaurav Nayyar, Yaya Chu, Mitchell S. Cairo
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 147

Showing 1-25 of 147 citing articles:

Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma
Pengfei Zhang, Chao Gao, Xiaoyong Huang, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 454
The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Tobias Bald, Matthew F. Krummel, Mark J. Smyth, et al.
Nature Immunology (2020) Vol. 21, Iss. 8, pp. 835-847
Open Access | Times Cited: 371
NK Cell Metabolism and Tumor Microenvironment
Iñigo Terrén, Ane Orrantia, Joana Vitallé, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 366
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
Meijun Zheng, Jianhan Huang, Aiping Tong, et al.
Molecular Therapy — Oncolytics (2019) Vol. 15, pp. 234-247
Open Access | Times Cited: 247
Multispecific drugs herald a new era of biopharmaceutical innovation
Raymond J. Deshaies
Nature (2020) Vol. 580, Iss. 7803, pp. 329-338
Closed Access | Times Cited: 225
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
Beatriz Sánchez-Correa, Isabel Valhondo, Fakhri Hassouneh, et al.
Cancers (2019) Vol. 11, Iss. 6, pp. 877-877
Open Access | Times Cited: 181
Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
Kyle B. Lupo, Sandro Matosevic
Cancers (2019) Vol. 11, Iss. 6, pp. 769-769
Open Access | Times Cited: 168
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Ahmet Yılmaz, Hanwei Cui, Michael A. Caligiuri, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 147
Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis
Rongqing Pan, Jeremy Ryan, Deng Pan, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1521-1538.e18
Open Access | Times Cited: 132
Hallmarks of Resistance to Immune-Checkpoint Inhibitors
Maria Karasarides, Alexandria P. Cogdill, Paul B. Robbins, et al.
Cancer Immunology Research (2022) Vol. 10, Iss. 4, pp. 372-383
Open Access | Times Cited: 77
NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions
Heyong Luo, Yanhua Zhou, Jing Zhang, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 53
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Beibei Zhang, Mengzhe Yang, Weimin Zhang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 29
CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts
Yu Yang Ng, Johan Chin-Kang Tay, Shu Wang
Molecular Therapy — Oncolytics (2019) Vol. 16, pp. 75-85
Open Access | Times Cited: 121
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Aviad Ben‐Shmuel, Guy Biber, Mira Barda‐Saad
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 117
Targeting Natural Killer Cells for Tumor Immunotherapy
Cai Zhang, Yuan Hu, Chongdeng Shi
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 100
CAR-NK Cells: From Natural Basis to Design for Kill
Muhammad Babar Khawar, Haibo Sun
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 98
On‐Chip Biogenesis of Circulating NK Cell‐Derived Exosomes in Non‐Small Cell Lung Cancer Exhibits Antitumoral Activity
Yoon‐Tae Kang, Zeqi Niu, Thomas Hadlock, et al.
Advanced Science (2021) Vol. 8, Iss. 6
Open Access | Times Cited: 83
Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
Ji‐Eun Park, Seong‐Eun Kim, Bhumsuk Keam, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000873-e000873
Open Access | Times Cited: 73
Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
Michal Sheffer, Emily Lowry, Nicky A. Beelen, et al.
Nature Genetics (2021) Vol. 53, Iss. 8, pp. 1196-1206
Closed Access | Times Cited: 72
Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy
Cristina Zalfa, Silke Paust
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 71
Advances in NK cell production
Fang Fang, Siqi Xie, Minhua Chen, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 4, pp. 460-481
Open Access | Times Cited: 67
NK cell-based therapeutics for lung cancer
A. Graham Pockley, Peter Vaupel, Gabriele Multhoff
Expert Opinion on Biological Therapy (2019) Vol. 20, Iss. 1, pp. 23-33
Closed Access | Times Cited: 70
Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies
Dana L. Casey, Nai‐Kong V. Cheung
Cancer Immunology Research (2020) Vol. 8, Iss. 2, pp. 161-166
Open Access | Times Cited: 67
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK
Amber Giles, Shuyu Hao, Michelle R. Padget, et al.
JCI Insight (2019) Vol. 4, Iss. 20
Open Access | Times Cited: 57
A three-dimensional hyaluronic acid-based niche enhances the therapeutic efficacy of human natural killer cell-based cancer immunotherapy
Young Ha Ahn, Long Ren, Seok‐min Kim, et al.
Biomaterials (2020) Vol. 247, pp. 119960-119960
Closed Access | Times Cited: 50
Page 1 - Next Page

Scroll to top